In addition, PRKN inhibits glioma cell growth in vitro and in vivo by downregulating the intracellular levels of β-catenin and EGFR, leading to decreased activation of both Wnt- and EGF-stimulated pathways (Lin et al., 2015). The gene discussed is EGF; the disease is central nervous system cancer.